Latest News in the pharma Industry

Research & Development

MannKind and Sanofi to terminate Afrezza license and collaboration agreement

MannKind and Sanofi to terminate Afrezza license and collaboration agreement

5 Jan 2016

MannKind is now reviewing its strategic options for Afrezza

Read more 
Merck, Pfizer and Syndax announce collaboration to evaluate combination of avelumab and entinostat in ovarian cancer

Merck, Pfizer and Syndax announce collaboration to evaluate combination of avelumab and entinostat in ovarian cancer

4 Jan 2016

The three companies will collaborate to investigate safety, tolerability and preliminary efficacy of avelumab and entinostat in advanced ovarian cancer.

Read more 
Epizyme announces first patient dosed in global clinical program evaluating tazemetostat in genetically defined solid tumours

Epizyme announces first patient dosed in global clinical program evaluating tazemetostat in genetically defined solid tumours

31 Dec 2015

US study sites now enrolling adults in registration-supporting Phase II study.

Read more 
Cellectis files first clinical trial application for UCART19, for hematological malignancies

Cellectis files first clinical trial application for UCART19, for hematological malignancies

31 Dec 2015

UCART19 is an allogeneic gene edited CAR T-cell product.

Read more 
Teikoku Pharma USA, Inc. announces FDA approval of docetaxel injection

Teikoku Pharma USA, Inc. announces FDA approval of docetaxel injection

30 Dec 2015

First non-alcohol formulation approved in the US.

Read more 
Seattle Genetics and BMS announce initiation of Phase I/II clinical trial of Adcetris in combination with Opdivo in relapsed or refractory non-Hodgkin lymphoma

Seattle Genetics and BMS announce initiation of Phase I/II clinical trial of Adcetris in combination with Opdivo in relapsed or refractory non-Hodgkin lymphoma

30 Dec 2015

Second of two planned trials combining Adcetris and Opdivo under clinical collaboration agreement.

Read more 
Actelion receices FDA approval of Uptravi  for the treatment of pulmonary arterial hypertension

Actelion receices FDA approval of Uptravi for the treatment of pulmonary arterial hypertension

30 Dec 2015

Uptravi will be made available to patients in the US in early January 2016.

Read more 
Boston Therapeutics' sugardown in clinical trials reduces glucose, fructose and insulin

Boston Therapeutics' sugardown in clinical trials reduces glucose, fructose and insulin

29 Dec 2015

sugardown reduces total glycemic index including fructose by up to 28% and insulin by up to 18%.

Read more 
Stellar Biotechnologies presents research on nanofiltration development at PepTalk Conference

Stellar Biotechnologies presents research on nanofiltration development at PepTalk Conference

26 Jan 2016

The presentation reported data from the company's development and validation of filtration methods for the removal of viruses during manufacturing processes of KLH products.

Read more 
APAC multiple myeloma therapy market hit $1.7 billion in 2014 and will add $1.1 billion by 2021

APAC multiple myeloma therapy market hit $1.7 billion in 2014 and will add $1.1 billion by 2021

23 Dec 2015

Emergence of novel therapeutics and minimal generic competition in China, Japan and Australia will drive APAC multiple myeloma market growth to 2021, says GBI Research.

Read more 
Merck and Pfizer advance clinical development program with two additional phase III trials of avelumab

Merck and Pfizer advance clinical development program with two additional phase III trials of avelumab

22 Dec 2015

Merck-Pfizer Alliance achieves 2015 goal of initiating six pivotal trials with JAVELIN Ovarian 200 and JAVELIN Bladder 100 trials.

Read more 
Boehringer Ingelheim's third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with NSCLC

Boehringer Ingelheim's third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with NSCLC

22 Dec 2015

FDA designation reinforces potential for BI 1482694 to become a new treatment option for patients with EGFR mutation-positive lung cancer with a T790M mutation.

Read more